OptimizeRx disclosed that total revenue for Q1 2026 declined year-over-year, impacted by reduced prescription recommendation service volumes, but did not provide specific dollar amounts. Earnings metrics showed margin pressure leading management to reassess resource allocation.

The company’s AI-powered digital health platform achieved double-digit usage growth, driven by new integrations with pharmaceutical partners and expanded deployment across provider networks. Executives highlighted that AI engagements now represent a growing share of total bookings and support future commercialization efforts.

To offset revenue headwinds, management introduced targeted restructuring measures, aiming to lower operating expenses through headcount adjustments and technology optimization. These changes are expected to improve EBITDA margins in the second half of 2026 as the company refocuses on high-growth AI solutions.